

INSTITUTIONAL BIOSAFETY COMMITTEE

**Tuesday, 10/21/2025 12:08 PM
 MSBII 5A116**

Chairperson

Mingtao Zeng, PhD

Board Members

Anthony W Baird, DSc
 Jeana E. Barrow, DVM
 Huanyu Dou, MD
 Pallavi Dubey, PhD
 Ivan E Flores, BS
 Daniel Gonzales, BA
 Sehrish Javaid, PhD

Administrative Staff

Amanda Ortiz
 Myrna Arvizo

MEMBERS PRESENT
Anthony W Baird, DSc, Jeana E. Barrow, DVM, Huanyu Dou, MD, Pallavi Dubey, PhD, Ivan E Flores, BS, Daniel Paul Gonzales, BMS, Sehrish Javaid, BDS, MS, PhD, Mingtao Zeng, PhD
MEMBERS ABSENT
N/A
STAFF PRESENT
Barbara S Castellanos, M.S., Amanda Diazdeleon
GUESTS PRESENT
N/A

CALL TO ORDER

Mingtao Zeng, PhD called the meeting to order at 12:08 p.m. Quorum is 5 members. 7 members are present at the call to order, including scientific, non-scientific and non-affiliated members. 8 members present at conclusion.

All proceedings and discussion in the upcoming meeting are confidential and should not be discussed outside of the meeting. Additionally, any member who has a conflict of interest that would preclude making an objective determination about a study should recuse him/herself from voting on the study.

A draft of the meeting minutes from 09/16/2025 was distributed for review on 09/25/2025. There were no controversial entries or objections. A motion to approve the meeting minutes as written was made by AB and

seconded by HD. The committee voted unanimously to approve the minutes.

The meeting was adjourned at 12:32 p.m.

MISCELLANEOUS

N/A

3-YEAR RENEWALS

N/A

AMENDMENTS

N/A

INITIAL REVIEWS

IBC# 26004

Full Renewal Expiration Date:

Hareesh Babu Bhaskaran Nair, PhD/TTUHSC El Paso - GSBS - Students-Graduate School of Biomedical Sciences

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI has responded to the concerns of the reviewers.

1. Section 5.1 The Lay Summary and study information are exact copies. A Lay Summary is a brief, easy-to-understand explanation of complex or technical information, written for a general audience without specialized scientific or medical knowledge.
2. Section 6.1 lists two chemicals, but there was listed "EC359, HBS-101 or their analogues" in section 6.2 Describe how you will use the above listed chemical(s).
3. In section 6.1, please add DMSO (referenced further down in the protocol) to the chemicals list.
4. Section 6.3, First Aid Measures left empty
5. Section 8.1 Please check the box in Section 8.1 for using recombinant DNA.
6. In Section 9.4, "We will use human and nonhuman primate cell lines" does not match Section 7.8, as it only lists human cell lines.
7. In section 9.4, the paragraph references the use of human and nonhuman primate cell lines, however in section 7.8, only human cell lines were selected. Please revise for consistency.
8. In Section 9.8 did not address the question of "was HepB vaccine taken?"

MEMBER COMMENTS:

Comment:

1. Section 5.1 A Lay Summary needs to be an easy-to-understand writing without a scientific medical background.
2. Section 6.1 GHS Ratings need to be added.
3. Please clarify the use of human and nonhuman primate cell lines.

Comment:

No further comments.

RECOMMENDATIONS: Additional Information Required

STIPULATIONS: 1. Section 5.1 A Lay Summary needs to be an easy-to-understand writing without a scientific medical background.

2. 2. Section 6.1 GHS Ratings need to be added.
3. 3. Please clarify the use of human and nonhuman primate cell lines.

MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed the initial application at their full board meeting and determined that additional information or modifications are required.

Total Members Voting: **8** [For: **8** Absent: **0** Against: **0** Conflict of Interest: **0** Not Present: **0** Abstained: **0**]
SUBMISSION OUTCOME: Additional Information Required

IBC# 26004

Full Renewal Expiration Date:

Hareesh Babu Bhaskaran Nair, PhD/TTUHSC El Paso - GSBS - Students-Graduate School of

Biomedical Sciences

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Protocol Type: Initial Application

PI Request: Use of

Space: MSB-I 2205s, 2209s, 2210, 2212s, 2213s, 2215, 2216s, 2217s

Biological Agents: Lentivirus, Human Tissue, Cell Lines,

Chemicals: EC359, HBS-101

Controlled Substances: No

Biosafety Level: BSL-2

Hazardous Shipping & On-Campus Transport Training: Not required

Recombinant or Synthetic Nucleic Acids: Prokaryotic Vector, Eukaryotic Vector

Training Compliance: PI is pending LSE

The AV is also assigned since the PI has stated this will involve animal work.

MEMBER COMMENTS:

Comment:

In section 6.1, please add DMSO (referenced further down in the protocol) to the chemicals list.

In section 8.1, please make a section in the applicable boxes regarding the rDNA to be used.

In section 9.4, the paragraph references the use of human and nonhuman primate cell lines, however in section 7.8, only human cell lines were selected. Please revise for consistency.

Thank you for your detailed section regarding post dosing chemical labeling of cages and handling of animal waste!

Comment:

The Lay Summary and study information are exact copies. A Lay Summary is a brief, easy-to-understand explanation of complex or technical information, written for a general audience without specialized scientific or medical knowledge.

Section 6.1 lists two chemicals, but there was listed " **EC359, HBS-101 or their analogues**" in section 6.2
Describe how you will use the above listed chemical(s).

Section 6.3, First Aid Measures left empty

Please check the box in Section 8.1 for using recombinant DNA.

In Section 9.4, " **We will use human and nonhuman primate cell lines**" does not match Section 7.8, as it only lists human cell lines. In Section 9.8 did not address the question of "was HepB vaccine taken?"

Comment:

Inspection of the lab areas to be used on this protocol are either not set up yet or are areas that will be shared with a current PI. With both types of areas, Safety and BSO have no concerns at this time.

RECOMMENDATIONS: Additional Information Required

STIPULATIONS: 1. Section 5.1 The Lay Summary and study information are exact copies. A Lay Summary is a brief, easy-to-understand explanation of complex or technical information, written for a general audience without specialized scientific or medical knowledge.

2. Section 6.1 lists two chemicals, but there was listed "EC359, HBS-101 or their analogues" in section 6.2

Describe how you will use the above listed chemical(s).

3. In section 6.1, please add DMSO (referenced further down in the protocol) to the chemicals list.

4. Section 6.3, First Aid Measures left empty

5. Section 8.1 Please check the box in Section 8.1 for using recombinant DNA.

6. In Section 9.4, "We will use human and nonhuman primate cell lines" does not match Section 7.8, as it only lists human cell lines.

7. In section 9.4, the paragraph references the use of human and nonhuman primate cell lines, however in section 7.8, only human cell lines were selected. Please revise for consistency.

8. In Section 9.8 did not address the question of "was HepB vaccine taken?"

SUBMISSION OUTCOME: Additional Information Required

EXPEDITED REVIEW

IBC# 26002

Full Renewal Expiration Date: 09/30/2028

Mei-Zhen Cui, PhD/TTUHSC El Paso - SOM - MTM-CoE in Diabetes and Metabolism

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI has responded to the last stipulation in section 9.8.

MEMBER COMMENTS:

Comment:

The PI has adequately addressed my comment, no other issue of concern. I recommend for IBC approval.

RECOMMENDATIONS: Approve

SUBMISSION OUTCOME: Approved

IBC# 26002

Full Renewal Expiration Date:

Mei-Zhen Cui, PhD/TTUHSC El Paso - SOM - MTM-CoE in Diabetes and Metabolism

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

MEMBER COMMENTS:

Comment:

The PI has responded to the concerns of the reviewers.

1. Section 8.3 Please add adenoviruses

2. Sections 9.2, 9.3, 9.4, 9.5, 9.6, 9.7 Please add adenoviruses

3. Section 9.8 Multiple human cell lines will be used. HepB vaccination should be provided to researchers by university occupational health office.

4. In section 9.13, please elaborate on the containment practices that will be used with the chemical and biologicals on this protocol.

5. Section 9.13 BSC should be selected, at least.

6. Section 9.17 Both Small Spill and Large Spill should be selected.

7. Contact Safety Services Daniel.P.Gonzales@ttuhsc.edu for proper BSL2 signage and lab inspection.

MEMBER COMMENTS:

Comment:

9.8 * If working with human materials, has HepB vaccine been offered?

PI should select "Yes" for this question.

Comment:

Met personally with PI and addressed locations to be used, correct signage, proper PPE, and information for IBC license. All requests from Safety have been taken care of and Safety/BSO approves this license.

Comment:

Are there any other lab staff that need to be added to this protocol?

Comment:

RECOMMENDATIONS: Additional Information Required

STIPULATIONS: 1. 9.8 * If working with human materials, has HepB vaccine been offered? PI should select "Yes" for this question.

SUBMISSION OUTCOME: Additional Information Required

IBC# 18024

Full Renewal Expiration Date: 08/31/2026

Alejandro Robles, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**Comment:**

This amendment designates Alejandro Robles, MD as the new Principal Investigator on the Institutional Biosafety License following the passing of Richard McCallum, MD. Dr Robles acknowledges that he will fulfill the responsibilities of the PI.

MEMBER COMMENTS:**Comment:**

I recommend IBC approval for the change of the PI, if the new PI has completed required training.

Comment:

RECOMMENDATIONS: Approve

SUBMISSION OUTCOME: Approved

IBC# 23005

Full Renewal Expiration Date: 05/31/2026

Chanwit Roongsritong, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**MEMBER COMMENTS:****Comment:**

Personnel change: Dr. Roongsritong will be leaving the institution, and Dr. Borges will assume responsibility for his IBC license. Dr. Roongsritong will remain listed as a co-investigator until his departure.

Dr. Roongsritong and Dr. Borges have already met to discuss the transition.

In addition, Jaime Richardson will be removed from the license, as she will be leaving TTUHSC.

LSE for Dr. Borges is still pending.

MEMBER COMMENTS:**Comment:**

This study requires hazardous material transportation/shipment training. Please make sure the completion of shipment training.

Study Application:

Section 9.13: Is there a Biological Safety Cabinet (BSC) available in the laboratory (MSB2 4B506 Bays D and E)? It is recommended to handle/process these clinical specimens inside BSC under BSL2 precaution in the laboratory. Section 9.17: The researchers need to know how to deal with "large spill" if possible. Please also select the second selection "if large spill..."

RECOMMENDATIONS: Additional Information Required

STIPULATIONS: This study requires hazardous material transportation/shipment training. Please make sure the completion of shipment training.

2. Study Application: Section 9.13: Is there a Biological Safety Cabinet (BSC) available in the laboratory (MSB2 4B506 Bays D and E)?

3. It is recommended to handle/process these clinical specimens inside BSC under BSL2 precaution in the laboratory.

4. Section 9.17: The researchers need to know how to deal with "large spill" if possible. Please also select the second selection "if large spill..."

SUBMISSION OUTCOME: Additional Information Required

IBC# 26001

Full Renewal Expiration Date: 09/30/2028

Xuemin Xu, PhD/TTUHSC El Paso - SOM - MTM-CoE in Neurosciences

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

MEMBER COMMENTS:

Comment:

The PI has responded to the concerns of the reviewer. The addition of personnel will be submitted through an amendment. Safety please ensure that the lab is approved for research activities. STIPULATIONS: 1. Section 6.2 and 6.3 remove Recombinant/Synthetic Nucleic Acids and add to sections 8.1-8.9.2. Section 8.3: Please list adenovirus and lentivirus vectors and describe them. 3. Section 8.5: Please specify what gene fragments will be cloned into the vectors. 4. Section 8.6: Please specify what proteins will be expressed. 5. Section 9.2, 9.5, 9.6, 9.7: Please add: Recombinant adenovirus and lentivirus vectors, list precaution BSL26. Section 9.8: Multiple human cell lines will be used in the research. HepB vaccine is recommended for all staff involved in the research. HepB vaccine is available and provided by the University Occupational Health office. Personnel will be added through an amendment.

MEMBER COMMENTS:

Comment:

The PI has adequately addressed reviewer's comments. I recommend for IBC approval of this protocol.

Comment:

Met personally with PI and addressed locations to be used, correct signage, proper PPE, and information for IBC license. All requests from Safety have been taken care of and Safety/BSO approves this license.

Comment:

Are there any other lab members that need to be added to this protocol?

RECOMMENDATIONS: Approve

SUBMISSION OUTCOME: Approved

ADMINISTRATIVE-ANNUAL STATUS REPORTS

IBC# 21013

Full Renewal Expiration Date: 10/31/2027

Eugene P Toy, MD/TTUHSC El Paso - SOM - Obstetrics and Gynecology-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does not include shipper and on-campus training. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 12001SA

Full Renewal Expiration Date: 10/31/2026

Mingtao Zeng, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2+

ADMINISTRATIVE COMMENT:

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does include shipper and on-campus training. This training is complete for those listed in section 5.5 and 5.6. The biosafety level is 2. This protocol does involve recombinant or synthetic nucleic acid molecules. Select Agents and Toxins (ID 13951) training is current for the PI. A notice was sent on 9/26 for JC to complete the Select Agent Toxins training in CITI. The training was completed on 10/03.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 18024

Full Renewal Expiration Date: 08/31/2026

Alejandro Robles, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does include shipper and on-campus training. This training is complete for those listed in section 5.5 and 5.6. The biosafety level is 2. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 22001

Full Renewal Expiration Date: 10/31/2027

Fernanda Payan Schober, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

MEMBER COMMENTS:

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does include shipper and on-campus training. This training is complete for those listed in section 5.5 and 5.6. The biosafety level is 2. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

ADMINISTRATIVE-AMENDMENTS

IBC# 10010

Full Renewal Expiration Date: 07/31/2028

Mingtao Zeng, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2+

ADMINISTRATIVE COMMENT:

MEMBER COMMENTS:

Comment:

Personnel change to add Jorge Ortiz and Maryam Amin. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 14005

Full Renewal Expiration Date: 05/31/2026

Munmun Chattopadhyay, PhD/TTUHSC El Paso - SOM - MTM-CoE in Diabetes and Metabolism

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

MEMBER COMMENTS:

Comment:

Personnel change to add Stephanie Chavez and Ithzel Dominguez. COI, FD, and LSE are complete. Also remove Brianna Morales. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 19004

Full Renewal Expiration Date: 05/31/2028

Irene Sarosiek, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Alejandro Robles, COI, FD, and LSE are complete. Remove Dr. McCallum who is no longer participating in research. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: 1. Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 25002

Full Renewal Expiration Date: 12/31/2027

Murali Bagalur Muniraju, Ph.D./TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Danei Romero, Mahek Mirza, America Rodriguez, and Jazmine Ramirez . COI, FD, and LSE are complete. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 22008

Full Renewal Expiration Date: 09/30/2028

Subodh Kumar, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Daniela Rodarte, Rebecca Yohannes, Sreeja Eadha, Peter Zotor, Kobie Payan, , Tony Paul, Karen Vega Jesus Guerrero. Remove Aditi, Angelica, Yogyana, and Davin. Training is complete.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 25008

Full Renewal Expiration Date: 09/30/2028

Darby Carmelle Ghislaine Mayer/TTUHSC El Paso - SOM - Medical Education

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI previously addressed the reviewers' concerns; however, not all responses were entered into the application. All concerns were documented and answered on the Submission Response form.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 25009

Full Renewal Expiration Date: 08/31/2028

Shilpa Singh, DDS BDS MS/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment: Personnel change to add Gilberto Garcia, Daniela Rodarte, and Martin Marrufo. COI, LSE, and the Research FD are current.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 26001

Full Renewal Expiration Date: 09/30/2028

Xuemin Xu, PhD/TTUHSC El Paso - SOM - MTM-CoE in Neurosciences

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Laura Perez Velasco and Daniela Nettik. COI, FD, and LSE are complete. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 26002

Full Renewal Expiration Date: 09/30/2028

Mei-Zhen Cui, PhD/TTUHSC El Paso - SOM - MTM-CoE in Diabetes and Metabolism

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Kennya Gomez. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules. The PI is also updating their lab spaces that have been approved by Safety Services.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 26001

Full Renewal Expiration Date: 09/30/2028

Xuemin Xu, PhD/TTUHSC El Paso - SOM - MTM-CoE in Neurosciences

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment: The PI is updating the lab spaces per Safety Services, 4004 (Chemical hood) 4007 (Tissue culture room with safety cabinet) 4015.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 25005

Full Renewal Expiration Date: 07/31/2028

Julianna Santos/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Faheem Sheriff and Sonia Banjara. Remove Liam Conner and Ayse Holt who are not active on this project. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 22001

Full Renewal Expiration Date: 10/31/2027

Fernanda Payan Schober, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This is a personnel change to remove Adriana Mares and Diego Escobar-Garcia from the shipping section of the study application. They are no longer with the institution/working in the lab. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 23006

Full Renewal Expiration Date: 01/30/2027

Jonathan Lavezo, MD/TTUHSC El Paso - SOM - Pathology

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to remove Jaime Richardson and add Hector Ruiz. Training is complete for Hector Ruiz.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 15019

Full Renewal Expiration Date: 01/31/2027

Peter Thompson, MD/TTUHSC El Paso - SOM - Psychiatry-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Javier Morales. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 23001

Full Renewal Expiration Date: 09/30/2028

Nils P Nickel, MD/TTUHSC El Paso - SOM - Internal Medicine-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment: Personnel change to remove Jaime from the application. No license needed.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 25008

Full Renewal Expiration Date: 09/30/2028

Darby Carmelle Ghislaine Mayer/TTUHSC El Paso - SOM - Medical Education

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Sarah Ali and Ethan Tran. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

TERMINATIONS

N/A

BSO REPORT

There were no major deficiencies reported.